https://www.aigom.it/wp-content/uploads/2026/09/ART29.9.png737500Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-09-29 13:40:242026-09-29 13:57:24CLINICAL VALIDATION OF A CIRCULATING TUMOR DNA-BASED BLOOD TEST TO SCREEN FOR COLORECTAL CANCER.
https://www.aigom.it/wp-content/uploads/2026/09/ART.22.9.png672450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-09-22 08:39:242026-09-22 08:39:24A META-ANALYSIS IDENTIFIES DRIVER GENES AND CHARACTERIZES THE MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCER.
https://www.aigom.it/wp-content/uploads/2026/09/COP.15.9-1.png609500Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-09-15 08:44:562026-09-15 08:47:19EXPLORING ALTERNATIVES TO TUMOR TISSUE FOR BRCA1/2 NEXT-GENERATION SEQUENCING TESTING IN HIGH-GRADE SEROUS OVARIAN CANCER: A 34-CASE OF MALIGNANT ASCITES.
https://www.aigom.it/wp-content/uploads/2026/07/ART217A-1.png606400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-21 15:42:512026-07-21 16:16:48THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH DRIVER ALTERATIONS: ASCO LIVING GUIDELINE, 2026.3.1.
https://www.aigom.it/wp-content/uploads/2026/07/art14.7-copertina.png692450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-14 16:21:302026-07-14 16:21:30PREDICTING THE PROGNOSIS OF BREAST CANCER BY USING NUTRION-BASED INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS.
https://www.aigom.it/wp-content/uploads/2026/07/art7.7.png651400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-07 07:43:362026-07-07 07:43:36DEFINING CARDIOVASCULAR ENDPOINTS IN ONCOLOGY TRIALS: CHALLENGES AND OPPORTUNITIES: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION.
https://www.aigom.it/wp-content/uploads/2026/06/ART30.6.png645450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-30 13:51:182026-06-30 13:51:18OPPORTUNISTIC SALPINGECTOMY FOR PREVENTION OF TUBO-OVARIAN CARCINOMA: THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY CONSENSUS STATEMENTS.
https://www.aigom.it/wp-content/uploads/2026/06/ART23.1.png714450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-23 06:35:132026-06-23 06:35:13THE PATHOLOGIC RESPONSE EVALUATION AND DETECTION IN CIRCULATING TUMOR-DNA STUDY: ULTRASENSITIVE CIRCULATING TUMOR-DNA ASSESSMENT OF BREAST CANCER MINIMAL RESIDUAL DISEASE.
https://www.aigom.it/wp-content/uploads/2026/06/ART9.6.png501400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-09 09:50:562026-06-09 09:50:56FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
